Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,11304902,AUC,"Mean alprazolam AUC was 210 and 202 ng.h/mL in the absence and the presence of alosetron, respectively.",Effect of alosetron on the pharmacokinetics of alprazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304902/),[h·ng] / [ml],210,1249,DB00969,Alosetron
,11304902,AUC,"Mean alprazolam AUC was 210 and 202 ng.h/mL in the absence and the presence of alosetron, respectively.",Effect of alosetron on the pharmacokinetics of alprazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304902/),[h·ng] / [ml],202,1250,DB00969,Alosetron
,11736869,Cmax,"Alosetron had no significant effect on theophylline plasma concentrations (Cmax approximately 9 microg ml(-1), AUC approximately 90 microg ml(-1) h) or oral formation clearance of three major metabolites produced via CYP1A2: 3-methylxanthine, 1-methylurate and 1,3-dimethylurate (5, 7 and 16 ml min(-1), respectively).",Effect of alosetron on theophylline pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736869/),[μg] / [ml],9,19144,DB00969,Alosetron
,11736869,AUC,"Alosetron had no significant effect on theophylline plasma concentrations (Cmax approximately 9 microg ml(-1), AUC approximately 90 microg ml(-1) h) or oral formation clearance of three major metabolites produced via CYP1A2: 3-methylxanthine, 1-methylurate and 1,3-dimethylurate (5, 7 and 16 ml min(-1), respectively).",Effect of alosetron on theophylline pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736869/),[h·μg] / [ml],90,19145,DB00969,Alosetron
,11736869,oral formation clearance,"Alosetron had no significant effect on theophylline plasma concentrations (Cmax approximately 9 microg ml(-1), AUC approximately 90 microg ml(-1) h) or oral formation clearance of three major metabolites produced via CYP1A2: 3-methylxanthine, 1-methylurate and 1,3-dimethylurate (5, 7 and 16 ml min(-1), respectively).",Effect of alosetron on theophylline pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736869/),[ml] / [min],5,19146,DB00969,Alosetron
,11736869,oral formation clearance,"Alosetron had no significant effect on theophylline plasma concentrations (Cmax approximately 9 microg ml(-1), AUC approximately 90 microg ml(-1) h) or oral formation clearance of three major metabolites produced via CYP1A2: 3-methylxanthine, 1-methylurate and 1,3-dimethylurate (5, 7 and 16 ml min(-1), respectively).",Effect of alosetron on theophylline pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736869/),[ml] / [min],7,19147,DB00969,Alosetron
,11736869,oral formation clearance,"Alosetron had no significant effect on theophylline plasma concentrations (Cmax approximately 9 microg ml(-1), AUC approximately 90 microg ml(-1) h) or oral formation clearance of three major metabolites produced via CYP1A2: 3-methylxanthine, 1-methylurate and 1,3-dimethylurate (5, 7 and 16 ml min(-1), respectively).",Effect of alosetron on theophylline pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736869/),[ml] / [min],16,19148,DB00969,Alosetron
,25761551,m/z,"For quantitative analysis, the multiple reaction monitoring transitions studied were m/z 295.1/201.0 for ALO and m/z 299.1/205.1 for IS in the positive ionization mode.",Application of a UPLC-MS/MS method for the analysis of alosetron in human plasma to support a bioequivalence study in healthy males and females. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25761551/),,295.1,35345,DB00969,Alosetron
,25761551,m/z,"For quantitative analysis, the multiple reaction monitoring transitions studied were m/z 295.1/201.0 for ALO and m/z 299.1/205.1 for IS in the positive ionization mode.",Application of a UPLC-MS/MS method for the analysis of alosetron in human plasma to support a bioequivalence study in healthy males and females. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25761551/),,201.0,35346,DB00969,Alosetron
,25761551,m/,"For quantitative analysis, the multiple reaction monitoring transitions studied were m/z 295.1/201.0 for ALO and m/z 299.1/205.1 for IS in the positive ionization mode.",Application of a UPLC-MS/MS method for the analysis of alosetron in human plasma to support a bioequivalence study in healthy males and females. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25761551/),,299.1,35347,DB00969,Alosetron
,25761551,m/,"For quantitative analysis, the multiple reaction monitoring transitions studied were m/z 295.1/201.0 for ALO and m/z 299.1/205.1 for IS in the positive ionization mode.",Application of a UPLC-MS/MS method for the analysis of alosetron in human plasma to support a bioequivalence study in healthy males and females. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25761551/),,205.1,35348,DB00969,Alosetron
,25761551,recovery,The assay recovery was within 97-103% for ALO and IS.,Application of a UPLC-MS/MS method for the analysis of alosetron in human plasma to support a bioequivalence study in healthy males and females. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25761551/),%,97-103,35349,DB00969,Alosetron
,11060667,bioavailability,"In pharmacokinetic studies, bioavailability of alosetron in healthy volunteers is approximately 60% and the plasma half-life is about 1.5 h.",Pharmacology and clinical experience with alosetron. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11060667/),%,60,60476,DB00969,Alosetron
,11060667,plasma half-life,"In pharmacokinetic studies, bioavailability of alosetron in healthy volunteers is approximately 60% and the plasma half-life is about 1.5 h.",Pharmacology and clinical experience with alosetron. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11060667/),h,1.5,60477,DB00969,Alosetron
,7751433,dose-normalized Cmax,"Mean pharmacokinetic parameters of haloperidol in the presence of alosetron and placebo treatments were not significantly (P > .05) different: dose-normalized Cmax (6.40 versus 5.75 ng/mL), dose-normalized Cmin (2.00 versus 1.90 ng/mL), dose-normalized AUC (85.97 versus 68.48 ng.hr/mL), and CL/f (78.23 versus 104.7 L/hr).",Effect of alosetron (a new 5-HT3 receptor antagonist) on the pharmacokinetics of haloperidol in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751433/),[ng] / [ml],6.40,88551,DB00969,Alosetron
,7751433,dose-normalized Cmax,"Mean pharmacokinetic parameters of haloperidol in the presence of alosetron and placebo treatments were not significantly (P > .05) different: dose-normalized Cmax (6.40 versus 5.75 ng/mL), dose-normalized Cmin (2.00 versus 1.90 ng/mL), dose-normalized AUC (85.97 versus 68.48 ng.hr/mL), and CL/f (78.23 versus 104.7 L/hr).",Effect of alosetron (a new 5-HT3 receptor antagonist) on the pharmacokinetics of haloperidol in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751433/),[ng] / [ml],5.75,88552,DB00969,Alosetron
,7751433,dose-normalized Cmin,"Mean pharmacokinetic parameters of haloperidol in the presence of alosetron and placebo treatments were not significantly (P > .05) different: dose-normalized Cmax (6.40 versus 5.75 ng/mL), dose-normalized Cmin (2.00 versus 1.90 ng/mL), dose-normalized AUC (85.97 versus 68.48 ng.hr/mL), and CL/f (78.23 versus 104.7 L/hr).",Effect of alosetron (a new 5-HT3 receptor antagonist) on the pharmacokinetics of haloperidol in schizophrenic patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751433/),[ng] / [ml],2.00,88553,DB00969,Alosetron
,7751433,dose-normalized Cmin,"Mean pharmacokinetic parameters of haloperidol in the presence of alosetron and placebo treatments were not significantly (P > .05) different: dose-normalized Cmax (6.40 versus 5.75 ng/mL), dose-normalized Cmin (2.00 versus 1.90 ng/mL), dose-normalized AUC (85.97 versus 68.48 ng.hr/mL), and CL/f (78.23 versus 104.7 L/hr).",Effect of alosetron (a new 5-HT3 receptor antagonist) on the pharmacokinetics of haloperidol in schizophrenic patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751433/),[ng] / [ml],1.90,88554,DB00969,Alosetron
,7751433,dose-normalized AUC,"Mean pharmacokinetic parameters of haloperidol in the presence of alosetron and placebo treatments were not significantly (P > .05) different: dose-normalized Cmax (6.40 versus 5.75 ng/mL), dose-normalized Cmin (2.00 versus 1.90 ng/mL), dose-normalized AUC (85.97 versus 68.48 ng.hr/mL), and CL/f (78.23 versus 104.7 L/hr).",Effect of alosetron (a new 5-HT3 receptor antagonist) on the pharmacokinetics of haloperidol in schizophrenic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751433/),[h·ng] / [ml],85.97,88555,DB00969,Alosetron
,7751433,dose-normalized AUC,"Mean pharmacokinetic parameters of haloperidol in the presence of alosetron and placebo treatments were not significantly (P > .05) different: dose-normalized Cmax (6.40 versus 5.75 ng/mL), dose-normalized Cmin (2.00 versus 1.90 ng/mL), dose-normalized AUC (85.97 versus 68.48 ng.hr/mL), and CL/f (78.23 versus 104.7 L/hr).",Effect of alosetron (a new 5-HT3 receptor antagonist) on the pharmacokinetics of haloperidol in schizophrenic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751433/),[h·ng] / [ml],68.48,88556,DB00969,Alosetron
,7751433,CL/f,"Mean pharmacokinetic parameters of haloperidol in the presence of alosetron and placebo treatments were not significantly (P > .05) different: dose-normalized Cmax (6.40 versus 5.75 ng/mL), dose-normalized Cmin (2.00 versus 1.90 ng/mL), dose-normalized AUC (85.97 versus 68.48 ng.hr/mL), and CL/f (78.23 versus 104.7 L/hr).",Effect of alosetron (a new 5-HT3 receptor antagonist) on the pharmacokinetics of haloperidol in schizophrenic patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751433/),[l] / [h],78.23,88557,DB00969,Alosetron
,7751433,CL/f,"Mean pharmacokinetic parameters of haloperidol in the presence of alosetron and placebo treatments were not significantly (P > .05) different: dose-normalized Cmax (6.40 versus 5.75 ng/mL), dose-normalized Cmin (2.00 versus 1.90 ng/mL), dose-normalized AUC (85.97 versus 68.48 ng.hr/mL), and CL/f (78.23 versus 104.7 L/hr).",Effect of alosetron (a new 5-HT3 receptor antagonist) on the pharmacokinetics of haloperidol in schizophrenic patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751433/),[l] / [h],104.7,88558,DB00969,Alosetron
,7751433,AUC ratios,"Mean AUC ratios of reduced haloperidol to haloperidol (0.18) in the presence of alosetron were similar to values obtained in the absence of alosetron, indicating that alosetron had no influence on the metabolism of haloperidol.",Effect of alosetron (a new 5-HT3 receptor antagonist) on the pharmacokinetics of haloperidol in schizophrenic patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751433/),,0.18,88559,DB00969,Alosetron
,10429744,bioavailability,Orally alosetron has approximately 60% bioavailability and a half-life of 1.5 h.,Review article: clinical pharmacology of alosetron. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10429744/),%,60,217117,DB00969,Alosetron
,10429744,half-life,Orally alosetron has approximately 60% bioavailability and a half-life of 1.5 h.,Review article: clinical pharmacology of alosetron. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10429744/),h,1.5,217118,DB00969,Alosetron
,11874386,clearance,"Mean clearance values were 504 vs 677 ml min(-1) in young females vs males (mean ratio 0.75), and 461 vs 670 ml min(-1) in elderly females vs males (mean ratio 0.69).",Sex and age differences in the pharmacokinetics of alosetron. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11874386/),[ml] / [min],504,243751,DB00969,Alosetron
,11874386,clearance,"Mean clearance values were 504 vs 677 ml min(-1) in young females vs males (mean ratio 0.75), and 461 vs 670 ml min(-1) in elderly females vs males (mean ratio 0.69).",Sex and age differences in the pharmacokinetics of alosetron. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11874386/),[ml] / [min],677,243752,DB00969,Alosetron
,11874386,clearance,"Mean clearance values were 504 vs 677 ml min(-1) in young females vs males (mean ratio 0.75), and 461 vs 670 ml min(-1) in elderly females vs males (mean ratio 0.69).",Sex and age differences in the pharmacokinetics of alosetron. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11874386/),[ml] / [min],461,243753,DB00969,Alosetron
,11874386,clearance,"Mean clearance values were 504 vs 677 ml min(-1) in young females vs males (mean ratio 0.75), and 461 vs 670 ml min(-1) in elderly females vs males (mean ratio 0.69).",Sex and age differences in the pharmacokinetics of alosetron. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11874386/),[ml] / [min],670,243754,DB00969,Alosetron
,11874386,Volume of distribution,"Volume of distribution was smaller in females (approximately 63 l) compared with males (approximately 84 l), regardless of age or the sex difference in body weight.",Sex and age differences in the pharmacokinetics of alosetron. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11874386/),l,63,243755,DB00969,Alosetron
,11874386,Volume of distribution,"Volume of distribution was smaller in females (approximately 63 l) compared with males (approximately 84 l), regardless of age or the sex difference in body weight.",Sex and age differences in the pharmacokinetics of alosetron. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11874386/),l,84,243756,DB00969,Alosetron
